LAUSR

Antibiotic resistance is an increasing phenomenon and has become a serious public health concern. Nowadays, limited therapeutic options exist for the treatment of invasive infections caused by drug-resistant strains, particularly methicillin-resistant Staphylococcus aureus (MRSA). The present study was conducted to analyze the published literature on the in vitro activity of tedizolid toward MRSA strains. A systematic literature search was conducted on the Web of Science, PubMed, Scopus, and Google Scholar electronic databases from January 2000 to December 2017 to cover all published articles relevant to our study. Then, 18 publications that met our inclusion criteria were selected for data extraction and analysis by the Comprehensive Meta-analysis software. The overall antibacterial activity of tedizolid on 10,119 MRSA isolates was estimated 0.25 and 0.5 μg/mL for MIC50 and MIC90 (minimum inhibitory concentration at which 50% and 90% of isolates were inhibited, respectively), respectively. The pooled prevalence of tedizolid susceptibility was estimated at 99.6% (95% confidence interval: 99.5-99.8%). Only 4 of 18 included publications have reported the antibacterial activity of tedizolid against linezolid-resistant isolates, of which the MIC range of tedizolid was 0.25-16 μg/mL. Of the four studies, all of the linezolid-resistant isolates were susceptible to tedizolid in one study, and in the other studies, the susceptibility rates were <50%. Based on the results of the systematic reviews, tedizolid had a promising antibacterial activity against MRSA isolates from different clinical sources. However, future studies are needed to provide clinical evidence to support these observations.